Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma
Stock Information for Marker Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.